B5.jpg b5_ph.jpg
Milestones

2022

  • Feb. 2022
    AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 – a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases
  • Jan. 2022
    AffaMed Therapeutics Doses First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA in China in Cataract Surgery Patients
  • Jan. 2022
    AffaMed Technologies Announces Successful Completion of First Patient Implantations of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in Boao, Hainan
  • Jan. 2022
    AffaMed Therapeutics Enters into a Licensing Agreement with Hanmi Pharmaceutical to Develop and Commercialize Risuteganib (Luminate®) as a First-In-Class Treatment for Intermediate Dry AMD Patients in Greater China

2021

  • Nov. 2021
    AffaMed Therapeutics Announces the Establishment of AffaMed Digital to Advance Digital Medicines
  • Nov. 2021
    Supplemental New Drug Application for DEXTENZA Approved by FDA for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
  • Oct. 2021
    AffaMed Therapeutics' Joint Venture Launched in Beijing to Advance Industry-Leading Solutions for Cataract Surgery in Greater China
  • Sep. 2021
    AffaMed Therapeutics Announces Completion of First Patient Dosing of AM006 for Early Parkinson's Disease
  • Sep. 2021
    AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases
  • Sep. 2021
    AffaMed Therapeutics and Allgenesis Biotherapeutics Announce License Agreement for AG-73305 in Greater China Region
  • May. 2021
    AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson’s Disease
  • May. 2021
    AffaMed Therapeutics Announces Appointment of Vijay Karwal as Chief Financial Officer
  • Mar. 2021
    AffaMed Therapeutics and SIFI announce Joint Venture to serve Greater China Market
  • Mar. 2021
    Affamed Therapeutics announces completion of over US$170 million series B financing and appoints Dr. Ji Li as President and Board Member

2020

  • Oct. 2020
    AffaMed Therapeutics and Ocular Therapeutix announce license agreement and collaboration for DEXTENZA® and OTX-TIC in Asia
  • Oct. 2020
    AffaMed Therapeutics and EverInsight Therapeutics merged with Dayao Zhao, M.D., Ph.D. appointed as CEO
  • Jun. 2020
    EverInsight Therapeutics and VistaGen Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

2019

  • Aug. 2019
    EverInsight Therapeutics established
  • Feb. 2019
    AffaMed Therapeutics partners with Samsung Bioepis to develop and commercialize biosimilars in China
  • Feb. 2019
    AffaMed Therapeutics established